Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma: Current results of a multicenter trial

German Myeloma Treatment Group

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

277 untreated multiple myeloma patients of stage I (n = 33), II (n=106) and III (n=138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n=14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-a maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was >36 months in stage II and 11 months in stage III patients.

Original languageEnglish (US)
Pages (from-to)458-460
Number of pages3
JournalOncology Research and Treatment
Volume13
Issue number6
DOIs
StatePublished - 1990

Keywords

  • Induction therapy
  • Maintenance treatment
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma: Current results of a multicenter trial'. Together they form a unique fingerprint.

Cite this